What Cravit 1.5% Treats: Main Uses and Benefits

Cravit 1.5% is generally used to treat external eye conditions caused by susceptible bacteria, applied across domains where additional symptomatic support is needed. This commonly includes conditions presenting with acute episodes like bacterial conjunctivitis and severe manifestations such as corneal ulcer (keratitis). The primary benefit is the targeting of the infection’s source, which supports the process of infection clearance.

---

This ophthalmic solution is relevant for managing symptoms that interfere with daily comfort, helping to alleviate discomforts like burning, foreign body sensation, and pain, while also reducing disruptive signs such as excessive mucopurulent discharge and severe ocular redness. This approach contributes to improved day-to-day comfort during periods of heightened symptoms.

“The treatment is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”

A key application is supportive management to lower the risk of infection following eye surgeries or after an eye injury. In these critical clinical scenarios, the medication assists in reducing the chance of bacterial contamination that could interfere with healing and recovery.

Quick Fact: Relief for Ocular Discomfort

Regulatory References

1. NIH DailyMed Label for Levofloxacin 1.5% Ophthalmic Solution

Cravit 1.5% (levofloxacin ophthalmic solution) is a prescription fluoroquinolone antibiotic used for the treatment of certain bacterial infections of the eye, such as corneal ulcer.

This medication is not suitable for all individuals. Patients should discuss their full medical history with their healthcare provider to determine if this treatment is appropriate.

---

Who Cannot Use Cravit 1.5%?

Cravit 1.5% is contraindicated and should not be used by individuals who have a history of hypersensitivity or an allergic reaction to:

• Levofloxacin (the active ingredient in Cravit)
• Other quinolone antibiotics (a class of drugs that includes ciprofloxacin, ofloxacin, and others)
• Any other ingredient contained within the Cravit 1.5% formulation.

Precautions for Use

Special care and discussion with a doctor are needed for certain groups:

• Children: Safety and effectiveness have not been established for children under the age of six years.
• Pregnancy and Breastfeeding: Use during these periods should only occur if the potential benefit justifies the potential risk, as determined by a healthcare provider.
• Contact Lenses: Patients with signs or symptoms of a bacterial eye infection, such as a corneal ulcer, must not wear contact lenses during the treatment period.

Interactions with other medicines and products

The interaction profile for Cravit 1.5% (Levofloxacin Ophthalmic Solution) is defined by its low systemic exposure following topical administration to the eye. This characteristic results in an interaction structure that lacks the complex metabolic and systemic interaction warnings found with oral or intravenous fluoroquinolones. Official government regulatory documents confirm that the minimal systemic absorption means no clinically significant interactions related to metabolic enzymes, drug transporters, food, alcohol, or herbal products are explicitly documented in the prescribing information.

Interaction-Related Restriction

The only interaction-related constraint is a formal contraindication based on class-wide hypersensitivity. The medicine is strictly prohibited from use in individuals with a known history of allergy or hypersensitivity reaction to the active substance, Levofloxacin, or to any other antibacterial agent belonging to the quinolone class. This restriction is conditional upon a patient's prior medical history and is classified as a severe 'do not combine' rule in the context of prior exposure.

Absence of Specific Interaction Rules

• Systemic Drug-Drug: No specific medicinal products or product classes are documented to cause exposure-altering effects (e.g., changes in plasma concentration) or pharmacodynamic effects (e.g., QTc prolongation) when co-administered with this topical solution.
• Timing Rules: Official labeling does not mandate any specific time separation rules for administering Cravit 1.5% in conjunction with other medicines, including other topical eye drops or ointments.
• Non-Medicinal Interactions: There are no specified warnings or restrictions concerning co-administration with meals, alcohol, or dietary supplements.

Dual Inhibition of Bacterial DNA Synthesis

The pharmacological action of Cravit 1.5% is rooted in the fluoroquinolone mechanism, which exerts a specific interference with the bacterial genetic machinery, leading to the bactericidal effect. This mechanism involves the inhibition of two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By binding to and stabilizing the enzyme-DNA cleavage complexes, the medication prevents the necessary re-ligation of DNA strands and causes lethal double-strand breaks within the bacterial chromosome. This disruption is the core molecular step that rapidly and irreversibly halts the bacteria's ability to maintain DNA structure.

Cascade Leading to Bactericidal Action

The resulting molecular damage initiates a mechanistic cascade that leads to bacterial cell death. The simultaneous prevention of DNA repair and the inability of Topoisomerase IV to separate daughter chromosomes during division imposes a strict replication block on the pathogen. This swift failure of essential functions results in the drug's bactericidal (cell-killing) effect, which is the physiological means by which susceptible bacterial cells are eliminated.

How Cravit 1.5% is Used: Official Administration Guidelines

Cravit 1.5% is a prescription anti-infective administered exclusively as a sterile topical ophthalmic solution (eye drops), intended for direct application to the eye. The use of this medicine follows a specific, time-phased schedule designed to ensure maximal local drug coverage. While dosing regimens may vary by region, the following represent the standard clinical guidelines for administration.

---

Labeled Dosing Schedule

Treatment Phase	Days	Dose (Drops)	Frequency	Administration Details
Initial Phase	Days 1 through 3	One to two	Every 30 minutes to 2 hours while awake	Requires two additional doses (approx. 4 and 6 hours after retiring)
Maintenance Phase	Day 4 to completion	One to two	Every 1 to 4 hours while awake	Total duration is determined by the healthcare provider

---

Administration and Procedural Rules

• Administration Route: The solution must be used topically on the surface of the eye only and must not be injected subconjunctivally or introduced into the anterior chamber.
• Sterility Precaution: To prevent contamination, the applicator tip of the bottle must not be touched by the fingers or come into contact with the eye or any other surface.
• Contact Lenses: Patients are instructed not to wear contact lenses during treatment for the conditions the solution is prescribed to manage.

Population-Specific Use

• Older Adults: No adjustment to the standard dosage is required for older adult patients.
• Pediatrics: The safety and effectiveness of the 1.5% solution have not been established for use in children below the age of six years.

Evidence for use in Bacterial Corneal Ulcer (Keratitis)

The research that evaluated the ophthalmic solution for bacterial corneal ulcer was primarily conducted through short-term Randomized Controlled Trials (RCTs). The studies were designed to measure endpoints related to the Clinical Cure Rate and the achievement of Microbiological Eradication—meaning the elimination of the specific bacteria causing the infection.

Studies provided measurements of both the clinical cure rates and the microbiological eradication status following the regimen used in the trials. The findings describe patterns observed over a short-term observation period, typically limited to approximately 15 days. Regulatory assessments documented that the measured clinical cure rates in certain trials were not always consistent with all pre-specified clinical endpoints. Limited data are available on the long-term status of patients after the initial short-term study period concludes.

Research on Perioperative Disinfection

Research exploring the solution's application in the perioperative setting for infection risk reduction involved prospective and randomized clinical trials. Supporting studies also used Pharmacokinetic (PK) analysis to measure the Drug Concentration in Ocular Tissues, such as the aqueous humor. Supporting research explored how the drug distributes locally within the eye.

The research identified limits in the consistency of microbiological eradication across all types of target bacteria. Findings described variable eradication patterns across different species, with certain bacteria showing different eradication rates compared to others.

Long-Term Studies and Follow-up

The primary evidence relies on short-term follow-up durations that correspond to the length of the infection treatment or the immediate perioperative period. Due to this study design, long-term effects are not fully established. There is limited information that extends beyond the short-term follow-up to describe the durability of the microbiological patterns.

Evidence in Special Populations

Key efficacy trials included pediatric patients aged six years and older. The findings reported apply to those specific populations studied. However, data for certain groups remain insufficient, such as children under the age of six years.

Areas of Research Uncertainty and Gaps

The consistency of eradication against all bacterial species observed varies. This variability contributes to the areas of research uncertainty regarding specific ocular flora. Overall, the available research provides context but does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References Label: LEVOFLOXACIN- levofloxacin solution/ drops (U.S. National Library of Medicine)

Common questions about Cravit 1.5% (FAQ)

Q: Is Cravit 1.5% used to treat all causes of eye redness and irritation?

A: Official product information indicates that Cravit 1.5% is an antibacterial medication intended only for the topical treatment of certain bacterial external eye infections. It is designed to work by killing susceptible bacteria. Therefore, this product is generally not intended for treating redness or irritation caused by non-bacterial sources like allergies or viruses.

---

Q: What is the general purpose of using this medication for eye surgery prophylaxis?

A: According to authoritative sources, levofloxacin ophthalmic solution is used in the perioperative setting. This means its purpose is to prevent the development of a bacterial infection both before and immediately after certain kinds of ophthalmic (eye) surgery.

---

Q: Is it normal to feel a mild stinging or burning sensation when applying Cravit 1.5%?

A: Regulatory documents report that transient ocular burning, stinging, and general eye pain or discomfort are commonly experienced adverse reactions. These effects are typically mild, occurring in a small percentage (approximately 1% to 3%) of patients during clinical trials.

---

Q: What are the signs of a rare, serious allergic reaction to levofloxacin in an eye drop?

A: Official safety information describes possible signs of a serious allergic reaction, which may occur even with topical eye drops. Signs that require immediate medical attention include rash or hives, severe itching, swelling of the face, lips, tongue, or throat, or difficulty breathing or swallowing.

---

Q: Are there any systemic (whole-body) side effects to be aware of when using antibiotic eye drops?

A: Official information indicates that the maximum concentration of the drug absorbed into the body after eye use is very low. However, systemic-type adverse reactions have still been reported in clinical trials, including headache, a sore throat (pharyngitis), and taste disturbance (dysgeusia).

---

Q: Is it safe to use lubricating or moisturizing eye drops at the same time as Cravit 1.5%?

A: Official product information recommends a time separation when using multiple topical ocular medications. If other eye drops, such as lubricants, are being used, it is generally recommended to wait a minimum of 5 to 15 minutes between applying the different types of drops.

---

Q: Does the use of this eye drop have any restrictions on driving or operating machinery?

A: Since temporary blurring of vision is a common side effect immediately following application, patients are advised to use care when driving or operating machinery until their eyesight is clear again.

---

Q: Can Cravit 1.5% affect how well other topical eye treatments, like glaucoma drops, work?

A: Regulatory guidance recommends spacing out applications to ensure that all prescribed eye treatments are absorbed effectively. Waiting at least 5 to 15 minutes before applying any other eye drops is recommended to mitigate the risk of dilution or 'washing out' the other medication.

---

Q: Can Cravit 1.5% be effective against non-bacterial infections, such as viral conjunctivitis?

A: No. Official documents classify Cravit 1.5% as an antibiotic medication. Its mechanism is designed specifically to kill susceptible bacteria and is not effective against infections that are caused by viruses.

---

Q: What should a patient do if they miss one application of Cravit 1.5%?

A: The official product label provides specific guidance for handling a missed application. This guidance often advises against doubling up on doses and specifies the timing for continuing the treatment schedule. It is advised not to use an extra amount to compensate for the missed one.

---

Q: How long after opening the bottle of Cravit 1.5% should the remaining solution be discarded?

A: Regulatory guidance focuses on maintaining sterility after the bottle has been used. According to the official storage conditions, the remaining solution should typically be discarded within 28 days of first opening the bottle, even if some medication remains.

---

Q: What should be done if eye symptoms appear to worsen after starting Cravit 1.5%?

A: Official safety information states that if symptoms do not begin to improve within two to three days, or if they appear to get worse, contacting a healthcare provider is recommended. The official labeling notes that if a superinfection (a new infection) or a worsening of the existing condition occurs, use of the medication should be discontinued.

---

Q: Does Cravit 1.5% contain Benzalkonium Chloride or other preservatives that may cause irritation?

A: Yes, official composition and excipient listings confirm that the medication contains Benzalkonium chloride as an inactive ingredient. This substance is a common preservative used in ophthalmic solutions.

---

Q: Are there any documented cases of Cravit 1.5% worsening existing nerve or tendon conditions?

A: Levofloxacin belongs to the fluoroquinolone antibiotic class. Regulatory warnings for this class highlight the potential for tendon rupture or nerve damage (peripheral neuropathy) when administered systemically (e.g., orally or by injection). This risk is not explicitly listed for the topical ophthalmic solution, reflecting its minimal absorption into the body.

---

Q: What are the signs that a bacterial infection may be developing resistance to Cravit 1.5%?

A: Official labeling indicates that prolonged use of the eye drop may result in the overgrowth of bacteria or fungi that are not susceptible to the medication. If this occurs, it would manifest as a lack of improvement or a worsening of the infection, which would require discontinuing the medication.

---

Q: Is it possible to overdose on Cravit 1.5% by accidentally applying too many drops?

A: Regulatory safety data indicates that accidental topical overdose is not expected to cause life-threatening symptoms because the total amount of drug in the entire bottle is very small. If local overdose occurs, the official guidance states that the eyes can be flushed with clean water.

---

Q: Why is it important not to stop using Cravit 1.5% even if the eye feels better quickly?

A: The patient counseling information stresses that the full prescribed course should be completed. Symptoms of the infection may begin to improve before the bacterial source is completely eliminated, and stopping the treatment too early may cause the infection to recur.

How to Store and Dispose of Cravit 1.5%?

Levofloxacin ophthalmic solution 1.5% (Cravit/Iquix) must be stored and handled according to specific regulatory requirements to maintain its sterility and potency.

---

Storage Requirements

• Temperature: Store the solution at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). The product must be kept away from heat and must not be frozen.
• Protection: The container must be protected from direct light and moisture and should be kept tightly closed when not in use.
• Child Safety: It is mandatory to store the medicine out of the sight and reach of children.
• Container Integrity: Avoid contaminating the applicator tip with material from the eye, fingers, or any other surface.

---

Disposal Instructions

Any outdated or remaining solution after the course of treatment is completed must be discarded and not kept. Patients should consult their healthcare professional or pharmacist for specific instructions on how to dispose of unused medicine, ensuring compliance with local requirements for pharmaceutical waste.